A Study in Schizophrenic Patients

• Status: Terminated
• Trial end date: 2012-09-01

Summary

This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.

• Phase: Phase 2

Details

• Lead Sponsor: Denovo Biopharma LLC; Eli Lilly and Company